Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514206 | 1.00 | TDP1 (0.56) | TDP1AKR1B1FBP1CYP1A2VCAM1 | |
| SCHEMBL6179100 | 0.83 | TDP1 (0.44) | TDP1AKR1B1FBP1CYP1A2MAPT | |
| SCHEMBL31514205 | 0.83 | TDP1 (0.49) | TDP1CYP1A2VCAM1MAPTMAPK1 | |
| SCHEMBL11164262 | 0.83 | TDP1 (0.49) | TDP1CYP1A2VCAM1MAPTMAPK1 | |
| SCHEMBL6646572 | 0.82 | TDP1 (0.60) | TDP1FBP1VCAM1TSHRMAPK1 | |
| SCHEMBL10920471 | 0.81 | ADRA2A (0.57) | TDP1FBP1VCAM1MAPTTSHR | |
| SCHEMBL6640405 | 0.80 | TDP1 (0.62) | TDP1FBP1VCAM1TSHRMAPK1 | |
| SCHEMBL9033491 | 0.79 | AKR1B1 (0.67) | TDP1AKR1B1CYP1A2VCAM1MAPT | |
| SCHEMBL55504 | 0.79 | AKR1B1 (0.65) | AKR1B1TSHRMAPK1MEN1LMNA | |
| SCHEMBL29397431 | 0.79 | AKR1B1 (0.65) | AKR1B1TSHRMAPK1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068452-A1 | GUANFACINE DERIVATIVES AND THEIR USE IN TREATING CANCER | NEGIO THERAPEUTICS (BE) | 2025-04-03 | — | — | WO | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| US-7449582-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-11-11 | — | — | US | disclosed |
| EP-1673343-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-10 | — | — | EP | disclosed |
| EP-1673343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-28 | — | — | EP | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| EP-0160962-B1 | IODOPROPARGYL ESTERS OF SUBSTITUTED PHENYLACETIC ACIDS, THEIR PREPARATION AND USE AS BIOCIDES | THE DOW CHEMICAL COMPANY (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4639541-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1987-01-27 | — | — | US | disclosed |
| EP-0160962-A2 | Iodopropargyl esters of substituted phenylacetic acids, their preparation and use as biocides | THE DOW CHEMICAL COMPANY (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4239901-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | TDP1 1219/4885AKR1B1 4210/4885FBP1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.